» Articles » PMID: 7510128

Enhanced Intracellular Stability and Efficacy of PEG Modified Dextranase in the Treatment of a Model Storage Disorder

Overview
Specialties Biochemistry
Biophysics
Date 1994 Mar 2
PMID 7510128
Citations 5
Authors
Affiliations
Soon will be listed here.
Abstract

A model for storage disorders was produced in the livers of mice by the administration of liposomally encapsulated FITC-dextran. Liposomally delivered dextranase was found to be more efficient in degrading the accumulated substrate as compared to the free enzyme. Dextranase was covalently modified with PEG, and liposomes were used as carriers for delivering the free and the modified enzyme to the liver at similar rates. The PEG-dextranase conjugate showed greater intracellular stability as compared to the native enzyme. Liposomally delivered PEG-dextranase, by virtue of its enhanced intracellular stability, could not only degrade the accumulated FITC-dextran, but could also prevent its further accumulation over a period of time. This enhanced intracellular stability of enzymes would be of importance in extending the catalytic life of therapeutically active enzymes and thereby improve their therapeutic potential for the treatment of intracellular storage disorders.

Citing Articles

Lysosomal enzyme replacement therapies: Historical development, clinical outcomes, and future perspectives.

Solomon M, Muro S Adv Drug Deliv Rev. 2017; 118:109-134.

PMID: 28502768 PMC: 5828774. DOI: 10.1016/j.addr.2017.05.004.


Strategies for delivery of therapeutics into the central nervous system for treatment of lysosomal storage disorders.

Muro S Drug Deliv Transl Res. 2014; 2(3):169-86.

PMID: 24688886 PMC: 3969788. DOI: 10.1007/s13346-012-0072-4.


Enhanced endothelial delivery and biochemical effects of α-galactosidase by ICAM-1-targeted nanocarriers for Fabry disease.

Hsu J, Serrano D, Bhowmick T, Kumar K, Shen Y, Kuo Y J Control Release. 2010; 149(3):323-31.

PMID: 21047542 PMC: 3073729. DOI: 10.1016/j.jconrel.2010.10.031.


New biotechnological and nanomedicine strategies for treatment of lysosomal storage disorders.

Muro S Wiley Interdiscip Rev Nanomed Nanobiotechnol. 2010; 2(2):189-204.

PMID: 20112244 PMC: 4002210. DOI: 10.1002/wnan.73.


Microbial dextran-hydrolyzing enzymes: fundamentals and applications.

Khalikova E, Susi P, Korpela T Microbiol Mol Biol Rev. 2005; 69(2):306-25.

PMID: 15944458 PMC: 1197420. DOI: 10.1128/MMBR.69.2.306-325.2005.